Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | PI4KA | P42356 | 2/20 | 0.75 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.75 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.75 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.75 |
| ▸ | DPP4 | P27487 | 1/20 | 0.75 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.75 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.75 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.75 |
| ▸ | GAPDH | P04406 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.75 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.75 |
| ▸ | STAT6 | P42226 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.75 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12746919 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA | |
| SCHEMBL25936 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA | |
| SCHEMBL29941460 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA | |
| SCHEMBL23050294 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA | |
| SCHEMBL12031327 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA | |
| SCHEMBL24538798 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA | |
| SCHEMBL2550330 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA | |
| SCHEMBL12150808 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA | |
| SCHEMBL25937 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA | |
| SCHEMBL16359957 | 1.00 | ADORA3 (0.75) | ADORA3ADORA1MEN1KMT2API4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 861 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| EP-3688173-B1 | IN VITRO METHOD OF MRNA DELIVERY USING LIPID NANOPARTICLES | INTELLIA THERAPEUTICS INC (US) | 2025-12-17 | — | — | EP | claimed |
| US-20250325702-A1 | COMPOSITIONS AND METHODS FOR EDITING A TRANSTHYRETIN GENE | BEAM THERAPEUTICS INC. (US) | 2025-10-23 | — | — | US | claimed |
| EP-4615425-A1 | BASE EDITING OF TRANSTHYRETIN GENE | Beam Therapeutics Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2025109169-A1 | IMPROVED METHOD FOR IDENTIFICATION OF NUCLEOTIDE MODIFICATIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-05-30 | — | — | WO | claimed |
| CN-120077136-A | SiRNA and drug for inhibiting Amyloid Precursor Protein (APP) gene expression and application thereof | 广州必贝特医药股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2025103457-A1 | SIRNA FOR INHIBITING LPA EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | claimed |
| WO-2025103453-A1 | SIRNA FOR INHIBITING ANGIOTENSINOGEN EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | claimed |
| CN-120020252-A | SiRNA for inhibiting LPA expression and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-20 | — | — | CN | claimed |
| CN-120005876-A | SiRNA for inhibiting expression of angiotensinogen and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-114076805-B | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-07-26 | — | — | CN | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| WO-2022109129-A1 | CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-114555188-A | Methods of treating diseases and disorders associated with APOC3 | 箭头药业股份有限公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2022104001-A1 | EXPANDED PROTEIN LIBRARIES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-19 | — | — | WO | claimed |
| WO-2022104366-A1 | CHEMICAL MODIFICATIONS FOR INHIBITING EXPRESSION OF ALDH2 | DICERNA PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| CN-114502204-A | RNA combinations and compositions with reduced immunostimulatory properties | 库尔维科公司 | 2022-05-13 | — | — | CN | claimed |
| US-20220125825-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2022-04-28 | — | — | US | claimed |
| WO-2022087011-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022081758-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125825-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | RNGTT, PHAX, HAVCR2 | ADORA3 1372/4885ADORA1 1419/4885MEN1 4660/4885 |
| US-20250325702-A1 | COMPOSITIONS AND METHODS FOR EDITING A TRANSTHYRETIN GENE | TTR, TTN, HTT | ADORA3 4450/4885ADORA1 4497/4885MEN1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.